Breaking News

Syngene Acquires First US Manufacturing Facility

The Baltimore Biologics Drug Substance facility will serve customers across human and animal health market segments.

By: Rachel Klemovitch

Assistant Editor

Syngene International Limited (Syngene), a global contract research, development, and manufacturing organization (CRDMO), has acquired its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines. The facility was purchased by Syngene subsidiary Syngene USA Inc., from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.).  The facility will expand Syngene’s global biologics footprint to serve its customers...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters